Status:
COMPLETED
Paroxetine-mediated GRK2 Inhibition to Reduce Cardiac Remodeling After Acute Myocardial Infarction
Lead Sponsor:
Insel Gruppe AG, University Hospital Bern
Conditions:
Cardiac Remodeling
Myocardial Infarction
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This study evaluates the off-target effect of paroxetine to reverse cardiac remodeling and improve left ventricular ejection fraction in patients after acute myocardial infarction. Half of the partici...
Detailed Description
Cardiac remodeling is characterized by a composite of structural, geometric, molecular, and functional changes of the myocardium, and is an important determinant of heart failure and cardiovascular ou...
Eligibility Criteria
Inclusion
- Anterior wall ST-segment elevation myocardial infarction
- Primary percutaneous coronary intervention (PCI) within 24 hours of symptom onset
- Left ventricular ejection fraction ≤ 45% within 48-96 hours after primary PCI (transthoracic echocardiography)
Exclusion
- Female patients at reproductive age (\<50 years)
- Known intolerance to paroxetine
- Inability to provide informed consent
- Currently participating in another trial before reaching first endpoint
- Current medical therapy with MAO-blocker (during, 14 days before, and 14 days after treatment with MAO-blocker), lithium, thioridazide, or pimozide
- Concomitant tamoxifen intake
- Previous myocardial infarction
- Previous revascularization procedure (percutaneous coronary intervention or coronary artery bypass grafting).
- Contraindication to cardiac magnetic resonance imaging
- Obvious or questionable inability to appropriately cooperate (alcohol, drugs etc.)
- Relevant nephropathy or hepatopathy
Key Trial Info
Start Date :
October 26 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2022
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT03274752
Start Date
October 26 2017
End Date
March 1 2022
Last Update
June 1 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Bern University Hospital, Department of Cardiology
Bern, Switzerland, 3010